CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
A recent abstract presented at GI ASCO 2021: Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
The UK National Cancer Research Institute (NCRI) has cited the CCTG PR13 study (RADICALS-RT) as one of their top three achievements of the year in their 2019-2020 annual report! https://www.ncri.org.uk/wp-content/uploads/NCRI-Prostate-Group-Annual-Report-2019-20.pdf
CCTG SR7: A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS-2), has been centrally activated.
The Regulatory Affairs Team Leader will lead the Regulatory Team for CCTG within the OCO. The core responsibilities include leadership to ensure compliance with national and international regulations essential to the compliant conduct of clinical trials, development and implementation of Standard Operating Procedures at the Operations and Statistics Centre at Queen's University and in support of partnering organizations, and providing guidance in alignment with CCTG strategic directions.
The CCTG Pharmacy Network is actively seeking pharmacy representation for a pharmacist representative for the Genitourinary Disease Site Committee and a pharmacist representative for the Steering Group from Quebec.
CCTG is hiring right now for several positions including; Clinical Trial Assistants, Study Coordinators and a Clinical Research Associate. The positions are open at the CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario. For more information about the current career opportunities with us please visit our Careers Page.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
For our Canadian member sites a COVID-19 reminder to keep the CCTG updated on trial activities at your site.
